GLP-1データベース

FDA承認の減量薬すべてに関する包括的でエビデンスに基づくプロファイル。

Ozempic

(semaglutide)

適応: 減量・2型糖尿病

Ozempic is a once-weekly injectable GLP-1 receptor agonist approved for type 2 diabetes, widely used off-label for weigh…

Novo Nordisk

(semaglutide)

適応: 減量

Wegovy is a higher-dose semaglutide injection specifically approved for chronic weight management in adults with obesity…

Novo Nordisk

(tirzepatide)

適応: 減量・2型糖尿病

Mounjaro is a once-weekly dual GIP/GLP-1 receptor agonist approved for type 2 diabetes, with significant weight loss eff…

Eli Lilly

(tirzepatide)

適応: 減量

Zepbound is a tirzepatide injection specifically approved for chronic weight management, offering the same dual-action m…

Eli Lilly

(liraglutide)

適応: 減量

Saxenda is a daily injectable GLP-1 receptor agonist approved for chronic weight management, an earlier-generation alter…

Novo Nordisk

(naltrexone-bupropion)

適応: 減量

Contrave is an oral combination of naltrexone and bupropion approved for chronic weight management, targeting appetite a…

Currax Pharmaceuticals